Figure 2
Chronic BCI-838-treatment for 3 months corrected cognitive deficits and reduced anxiety in amyloid precursor protein (APP) transgenic mice. (a) APP transgenic mice (APP E693Q) and wild-type littermates (7–10 months old) were given BCI-838 or vehicle p.o. for 3 months. BCI-838 treatment was associated with improved memory in both contextual conditioning and novel object recognition tasks (% time freezing where more freezing time means better memory; (contextual fear conditioning, n=14–18; P=0.048 NonTg+Veh vs Tg+Veh; P=0.036 Tg+Veh vs Tg+BCI-838); (cued fear conditioning, n=14–18): time exploring novel object(s) where more time spent at novel object(s) means better memory; (novel object recognition, n=14–18; P=0.083 NonTg+Veh vs Tg+Veh; P=0.017 Tg+Veh vs Tg+BCI-838)). (b) Reduction in anxiety was seen in BCI-838-treated APP transgenic mice in the elevated plus maze (% time in open arm where more time in open arm means less anxiety; n=12–18; P=0.024 Tg+Veh vs Tg+BCI-838). Data are presented as means±s.e.m. *P<0.05.
